Journal of Japan Veterinary Cancer Society
Online ISSN : 1884-3352
Print ISSN : 1884-3344
ISSN-L : 1884-3344
Current issue
Displaying 1-5 of 5 articles from this issue
  • Kazuhito Kodama, Keiko Kodama
    2023 Volume 12 Issue 1 Pages 1-6
    Published: May 31, 2023
    Released on J-STAGE: May 26, 2023
    Advance online publication: March 31, 2023

    A 4-year-old neutered male Scottish Terrier, weighing 10.4 kg, presented with hematuria for the past 10 days. Ultrasonography revealed multiple masses in the apex and trigone of the bladder. A catheter biopsy was performed, and the histopathological diagnosis was non-invasive urothelial carcinoma (transitional cell carcinoma) with low to medium grade pathological malignancy. Treatments with piroxicam alone, vinblastine and firocoxib, toceranib and firocoxib, and firocoxib alone resulted in a partial response or stable disease. The patient showed no regional lymph node metastasis or distant metastases, maintained stable disease, and had an excellent quality of life at 1681 days after the start of treatment.

    Download PDF (1721K)
  • Hideya Hori, Tsuyoshi Narita, Go Higuchi, Takuro Mori, Shota Kono, Ken ...
    2023 Volume 12 Issue 1 Pages 7-12
    Published: May 31, 2023
    Released on J-STAGE: May 26, 2023

    This case report describes a 10-year-old castrated male Russian Blue cat who was referred to the hospital for respiratory distress and coughing. Tests for FeLV and FIV infection were negative. Pleural fluid was removed and subjected to cytological and lymphocyte clonality analysis. Thoracic radiography and ultrasonography confirmed atelectasis in some pulmonary lobes. The cat was diagnosed with stage III small- to medium-cell T cell lymphoma, and was treated with prednisolone (5 mg/head) and L-asparaginase (10000 units/m2). With this treatment, the pleural effusion gradually subsided and respiratory signs improved. However, the cat developed decreased motor function of the hindlimbs, forelimbs, and tongue, leading to the administration of 1-(2-Chloroethyl)3-cyclohexyl-1-nitrosourea (CCNU) (10mg/head or 38 mg/m2) for suspected central nervous system infiltration of lymphoma. Neurological signs dramatically improved within seven days, and CCNU (15mg/head or 54 mg/m2) was administered five more times until day 284, after which it was replaced with chlorambucil (2mg/head every four days). On day 393, weight loss and abdominal lymphadenopathy were observed, and CCNU (10mg/head) was administered again on the day 407 but was ineffective. Unfortunately, the cat eventually died on the day 466 with marked abdominal lymphadenopathy.

    Download PDF (1759K)